In a research report issued today, Oppenheimer analyst Rohit Vanjani maintained an Outperform rating on OvaScience Inc (NASDAQ:OVAS) with a $60 price target, after hosting investor …
On April 6, analysts at Wedbush led by Liana Moussatos highlighted upcoming events in the biotech sector. Here is what to watch for: OvaScience Inc …
OvaScience (NASDAQ: OVAS) is still testing its Augment Treatment, but analysts seem optimistic about recent results. OvaScience focuses on developing fertility treatments.
In a research report released today, H.C.
In a research note published today, H.C.
In a research report issued today, Oppenheimer analyst Rohit Vanjani downgraded shares of OvaScience Inc (NASDAQ:OVAS) to Perform from an Outperform rating, as shares of OvaScience …
